Mobia Medical Reports Third Quarter 2026 Financial Results
Globe Newswire•05/11/2026•16:05 ET
0
Key Highlights
- ➤Q3 revenue $15.6 million, up 73% year over year
- ➤Full-year 2026 revenue guidance raised to $57.0 million-$57.5 million
- ➤Q3 gross margin reached 83.2%, versus 79.6% prior year
- ➤Q3 net loss widened to $17.3 million, despite loss per share improving
- ➤Average active territories increased to 40 from 22.5 year over year
Expert Statements
Richard Foust, President and Chief Executive Officer of Mobia Medical
“This quarter, we delivered our strongest results yet. Revenue growth of 73% reflects the strength of our commercial execution and the predictable nature of our patient funnel.”
Richard Foust, President and Chief Executive Officer of Mobia Medical
“Additionally, we were pleased to announce the inclusion of paired VNS in the updated AHA Stroke guidelines for 2026, serving as validation of our evidence-based approach to stroke recovery and further recognition of how Vivistim® Paired VNS™ Therapy can redefine what is possible for stroke survivors.”
Richard Foust, President and Chief Executive Officer of Mobia Medical
“With our continued commercial traction and expanding territory footprint we are making substantial progress in generating greater access and awareness for this profoundly underserved patient population.”
Delivers revenue growth of 73% in the third quarter and raises full year 2026 revenue guidance
AUSTIN, Texas, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today reported financial results for the quarter ended September 30, 2026.
Get started
Create a free account to read the full story.